The multinational Phase III clinical trial enrolled over 1,000 men and their female partners from 22 countries to measure improvement of sexual functioning while taking 30mg or 60mg of dapoxetine (taken one to three hours prior to intercourse) versus placebo.
The presented data from female partners reinforce the beneficial impact of dapoxetine treatment, demonstrating significant improvement in all four pre-defined endpoints for partners of men treated with dapoxetine 30mg or 60mg versus placebo over a 25-week period.
Importantly, these findings confirm results from a separate study investigating how premature ejaculation (PE) affects female partners, which confirmed the significant impact in terms of lower perceived control over ejaculation, lower satisfaction with sexual intercourse, higher ejaculation-related personal distress and/or interpersonal difficulty in the relationship when compared with female partners of men without PE.